Indications And Dose
Osteoporosis in postmenopausal women (but not recommended) ▶BY DEEP INTRAMUSCULAR INJECTION ▶Adult (female): 50 mg every 3 weeks.
PDF page 787
Loading InternPractice…
Drug reference
Osteoporosis in postmenopausal women (but not recommended) ▶BY DEEP INTRAMUSCULAR INJECTION ▶Adult (female): 50 mg every 3 weeks.
PDF page 787
Acute porphyrias p. 1120
PDF page 787
Cardiac impairment. diabetes mellitus. epilepsy. hypertension. migraine. skeletal metastases (risk of hypercalcaemia) ▶With oral use in the elderly Prescription potentially inappropriate (STOPP criteria) in patients with a current or recent history of upper gastrointestinal disease or bleeding (risk of relapse/exacerbation of oesophagitis, oesophageal ulcer or oesophageal stricture). See also Prescribing in the elderly p. 33.
PDF pages 787, 788
Bisphosphonates are adsorbed onto hydroxyapatite crystals in bone, slowing both their rate of growth and dissolution, and therefore reducing the rate of bone turnover.
PDF page 787
→Appendix 1: nandrolone
PDF page 787
Clitoris enlarged. dysphonia. hepatic disorders. hepatic neoplasm. hirsutism. hypertension. libido increased. nausea. oedema. skin reactions. sodium retention. urine flow decreased. virilism (with high doses including voice changes - sometimes irreversible) ▶Common or very common Alopecia. anaemia. arthralgia. asthenia. constipation. diarrhoea. dizziness. dysphagia. electrolyte imbalance. eye inflammation. fever. gastritis. gastrointestinal discomfort. headache. influenza like illness. malaise. myalgia. nausea. oesophageal ulcer (discontinue). oesophagitis (discontinue). pain. peripheral oedema. renal impairment. skin reactions. taste altered. vomiting ▶Uncommon Anaphylactic reaction. angioedema. bronchospasm. oesophageal stenosis (discontinue). osteonecrosis ▶Rare or very rare Atypical femur fracture. Stevens- Johnson syndrome
PDF pages 787, 788
Manufacturer advises caution in severe impairment (discontinue treatment if hepatic function worsens or if oedema, with or without congestive heart failure, develops).
PDF page 787
Use with caution—may cause sodium and water retention. l LESS SUITABLE FOR PRESCRIBING Nandrolone injection is less suitable for prescribing.
PDF page 787
MHRA/CHM ADVICE: BISPHOSPHONATES: ATYPICAL FEMORAL FRACTURES (JUNE 2011) Atypical femoral fractures have been reported rarely with bisphosphonate treatment, mainly in patients receiving long-term treatment for osteoporosis. The need to continue bisphosphonate treatment for osteoporosis should be re-evaluated periodically based on an assessment of the benefits and risks of treatment for individual patients, particularly after 5 or more years of use. Patients should be advised to report any thigh, hip, or groin pain during treatment with a bisphosphonate. Discontinuation of bisphosphonate treatment in patients suspected to have an atypical femoral fracture should be considered after an assessment of the benefits and risks of continued treatment. MHRA/CHM ADVICE: BISPHOSPHONATES: OSTEONECROSIS OF THE JAW (NOVEMBER 2009) AND INTRAVENOUS BISPHOSPHONATES: OSTEONECROSIS OF THE JAW—FURTHER MEASURES TO MINIMISE RISK (JULY 2015) The risk of osteonecrosis of the jaw is substantially greater for patients receiving intravenous bisphosphonates in the treatment of cancer than for patients receiving oral bisphosphonates for osteoporosis Endocrine system or Paget’s disease. Risk factors for developing osteonecrosis of the jaw that should be considered are: potency of bisphosphonate (highest for zoledronate), route of administration, cumulative dose, duration and type of malignant disease, concomitant treatment, smoking, comorbid conditions, and history of dental disease. All patients with cancer and patients with poor dental status should have a dental check-up (and any necessary remedial work should be performed) before bisphosphonate treatment, or as soon as possible after starting treatment. Patients should also maintain good oral hygiene, receive routine dental check-ups, and report any oral symptoms such as dental mobility, pain, or swelling, non-healing sores or discharge to a doctor and dentist during treatment. Before prescribing an intravenous bisphosphonate, patients should be given a patient reminder card and informed of the risk of osteonecrosis of the jaw. Advise patients to tell their doctor if they have any problems with their mouth or teeth before starting treatment, and if the patient wears dentures, they should make sure their dentures fit properly. Patients should tell their doctor and dentist that they are receiving an intravenous bisphosphonate if they need dental treatment or dental surgery. Guidance for dentists in primary care is included in Oral Health Management of Patients Prescribed Bisphosphonates: Dental Clinical Guidance, Scottish Dental Clinical Effectiveness Programme, April 2011 (available at www.sdcep.org.uk). MHRA/CHM ADVICE: BISPHOSPHONATES: OSTEONECROSIS OF THE EXTERNAL AUDITORY CANAL (DECEMBER 2015) Benign idiopathic osteonecrosis of the external auditory canal has been reported very rarely with bisphosphonate treatment, mainly in patients receiving long-term therapy (2 years or longer). The possibility of osteonecrosis of the external auditory canal should be considered in patients receiving bisphosphonates who present with ear symptoms, including chronic ear infections, or suspected cholesteatoma. Risk factors for developing osteonecrosis of the external auditory canal include: steroid use, chemotherapy, infection, an ear operation, or cotton- bud use. Patients should be advised to report any ear pain, discharge from the ear, or an ear infection during treatment with a bisphosphonate.
PDF pages 787, 788
There can be variation in the licensing of different medicines containing the same drug. Solution for injection EXCIPIENTS: May contain Arachis (peanut) oil, benzyl alcohol ▶Deca-Durabolin (Aspen Pharma Trading Ltd) Nandrolone decanoate 50 mg per 1 ml Deca-Durabolin 50mg/1ml solution for injection ampoules | 1 ampoule P £3.17 e BISPHOSPHONATES Bisphosphonates f
PDF page 787
Atypical femoral fractures Patients should be advised to report any thigh, hip, or groin pain during treatment with a bisphosphonate. Osteonecrosis of the jaw During bisphosphonate treatment patients should maintain good oral hygiene, receive routine dental check-ups, and report any oral symptoms. Osteonecrosis of the external auditory canal Patients should be advised to report any ear pain, discharge from ear or an ear infection during treatment with a bisphosphonate. eiiii F 765
PDF page 788
50 mg every 3 weeks.
First-line fragment. Read the complete Indications and Dose section above.
PDF page 787